Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Markus Barden"'
Autor:
Krasimira Aleksandrova, Jana Leise, Christoph Priesner, Murat Aktas, Michael Apel, Mario Assenmacher, Iris Bürger, Anne Richter, Pia Altefrohne, Christine Schubert, Astrid Holzinger, Markus Barden, Valerie Bezler, Michael von Bergwelt-Baildon, Peter Borchmann, Lilia Goudeva, Wolfgang Glienke, Lubomir Arseniev, Ruth Esser, Hinrich Abken, Ulrike Koehl
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionPoint-of-care (POC) manufacturing of chimeric antigen receptor (CAR) modified T cell has expanded rapidly over the last decade. In addition to the use of CD19 CAR T cells for hematological diseases, there is a growing interest in targetin
Externí odkaz:
https://doaj.org/article/f6589c518506495e91a9217ebb7da6b4
Autor:
Dennis Christoph Harrer, Sin-Syue Li, Marcell Kaljanac, Markus Barden, Hong Pan, Hinrich Abken
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Chimeric antigen receptor (CAR) T cells are “living drugs” that specifically recognize their target antigen through an antibody-derived binding domain resulting in T cell activation, expansion, and destruction of cognate target cells. The FDA/EMA
Externí odkaz:
https://doaj.org/article/2d292fc5486b4ce9af50e2613937e877
Autor:
Markus Barden, Astrid Holzinger, Lukas Velas, Marianna Mezősi-Csaplár, Árpád Szöőr, György Vereb, Gerhard J. Schütz, Andreas A. Hombach, Hinrich Abken
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
In engineered T cells the CAR is co-expressed along with the physiological TCR/CD3 complex, both utilizing the same downstream signaling machinery for T cell activation. It is unresolved whether CAR-mediated T cell activation depends on the presence
Externí odkaz:
https://doaj.org/article/e06e8704a97446f89d093d4b3e77ab95
Autor:
Dennis Christoph Harrer, Charlotte Schenkel, Valerie Bezler, Marcell Kaljanac, Jordan Hartley, Markus Barden, Hong Pan, Astrid Holzinger, Wolfgang Herr, Hinrich Abken
Publikováno v:
Cells, Vol 11, Iss 23, p 3839 (2022)
The advent of chimeric antigen receptor (CAR) T cells expedited the field of cancer immunotherapy enabling durable remissions in patients with refractory hematological malignancies. T cells redirected for universal cytokine-mediated killing (TRUCKs),
Externí odkaz:
https://doaj.org/article/aeee5390f8a54ab4aa48b29bc1d99847
Autor:
Hinrich Abken, Markus Chmielewski, Markus Barden, Lisa Hannappel, Andreas Hombach, Gunter Rappl, Agapios Sachinidis
Publikováno v:
Molecular Therapy. 30:593-605
Chimeric antigen receptor (CAR)-redirected T cell therapy often fails to control tumors in the long term due to selecting cancer cells that downregulated or lost CAR targeted antigen. To reprogram the functional capacities specifically of engineered
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfb4e09ae73b30ad97dad8d9ae4f0fc6
https://doi.org/10.1016/j.ymthe.2021.10.011
https://doi.org/10.1016/j.ymthe.2021.10.011
Autor:
Andreas, Hombach, Markus, Barden, Lisa, Hannappel, Markus, Chmielewski, Gunter, Rappl, Agapios, Sachinidis, Hinrich, Abken
Publikováno v:
Molecular therapy : the journal of the American Society of Gene Therapy. 30(2)
Chimeric antigen receptor (CAR)-redirected T cell therapy often fails to control tumors in the long term due to selecting cancer cells that downregulated or lost CAR targeted antigen. To reprogram the functional capacities specifically of engineered
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3309a305b147326865752686f20d0fd5
https://pubmed.ncbi.nlm.nih.gov/34678512
https://pubmed.ncbi.nlm.nih.gov/34678512
Autor:
Markus Bardenheuer
Publikováno v:
Early Modern Low Countries, Vol 2, Iss 2, Pp 301-303 (2018)
Externí odkaz:
https://doaj.org/article/44b2e0e1c430423f8f8b90d367c3535b